Table 3.
Pregnancy outcomes of two treatment protocols
| Original cohort | P | PSM cohort | P | |||
|---|---|---|---|---|---|---|
| Group A (n = 168) | Group B (n = 114) | Group A (n = 71) | Group B (n = 71) | |||
| Clinical pregnancy rate (n, %) | 83 (49.40%) | 73 (64.04%) | 0.015 | 33 (46.48%) | 43 (60.56%) | 0.130 |
| Miscarriage rate (n, %) | 21 (12.50%) | 20 (17.54%) | 0.238 | 10 (14.09%) | 11 (15.49%) | 0.813 |
| Early miscarriage | 17(10.12%) | 17(14.91%) | 0.225 | 8(11.27%) | 10(14.08%) | 0.796 |
| Late miscarriage | 4(2.38%) | 3(2.63%) | 0.894 | 2(2.81%) | 1(1.41%) | 0.560 |
| Live birth rate (n, %) | 62 (36.90%) | 52 (45.61%) | 0.144 | 23 (32.39%) | 32 (45.07%) | 0.168 |
| Single/twin | 0.079 | 0.214 | ||||
| Single (n, %) | 57(91.94%) | 42(80.77%) | 20 (86.96%) | 25 (78.12%) | ||
| Twin (n, %) | 5(8.06%) | 10(19.23) | 3 (13.04%) | 7 (21.88%) | ||
| Preterm delivery rate (n, %) | 15 (8.93%) | 15 (13.16%) | 0.258 | 5 (7.04%) | 11 (15.49%) | 0.185 |
| Cumulative live birth rate (n, %) | 87/168(51.79%) | 73/114(64.04%) | 0.042 | 39/71(54.90%) | 43/71(60.60%) | 0.610 |
Note: Group A = GnRH antagonist protocol and freeze-all strategy; Group B = long-acting GnRH agonist protocol; PSM = propensity-score matching